A 32-week gestation female infant born to a mother with poorly controlled gestational diabetes is admitted to the NICU at 4 hours of life with respiratory distress. Chest X-ray shows a fine reticular granular pattern with air bronchograms. Arterial blood gas shows pH 7.28, PaCO₂ 52 mmHg, PaO₂ 65 mmHg on 40% oxygen. The infant is intubated and given exogenous surfactant. Two hours post-surfactant, there is sudden onset of hypotension (mean BP 35 mmHg), bradycardia (HR 90), and reduced urine output. What is the most likely complication?

Explanation

## Pulmonary Hemorrhage: A Complication of RDS Treatment ### Clinical Context **Key Point:** Pulmonary hemorrhage is a rare but serious complication that can occur within hours after exogenous surfactant administration in preterm infants with RDS, particularly those at high risk (maternal diabetes, perinatal asphyxia, patent ductus arteriosus). ### Pathophysiology of Pulmonary Hemorrhage Post-Surfactant 1. **Rapid improvement in lung compliance:** Surfactant replacement dramatically reduces surface tension and improves alveolar ventilation and oxygenation. 2. **Sudden increase in pulmonary blood flow:** The rapid improvement in lung mechanics causes pulmonary vascular resistance to drop sharply, leading to increased left-to-right shunting (especially through a patent ductus arteriosus, common in preterm infants). 3. **Pulmonary capillary stress:** The sudden increase in pulmonary blood flow and capillary pressure overwhelms the fragile, immature capillary endothelium. 4. **Hemorrhage into alveoli:** Red blood cells leak into the alveolar space, causing pulmonary edema and hemorrhage. The infant may cough up or have endotracheal secretions that are blood-stained or frankly hemorrhagic. ### Clinical Presentation | Feature | Details | |---------|----------| | **Timing** | 2–12 hours post-surfactant administration | | **Respiratory signs** | Sudden worsening of oxygenation despite surfactant; pink or blood-tinged endotracheal secretions | | **Hemodynamic signs** | Hypotension, tachycardia (or bradycardia if severe), poor perfusion | | **Metabolic signs** | Metabolic acidosis, reduced urine output, signs of shock | | **CXR findings** | Acute bilateral infiltrates (may appear as "whiteout") | ### Risk Factors for Pulmonary Hemorrhage Post-Surfactant ```mermaid flowchart TD A[Preterm infant on surfactant]:::outcome --> B{Risk factors present?}:::decision B -->|PDA| C[Increased left-to-right shunt]:::action B -->|Maternal diabetes| D[Immature capillary endothelium]:::action B -->|Asphyxia| E[Capillary injury + RDS]:::action B -->|Sepsis| F[Inflammatory capillary leak]:::action C --> G[Pulmonary capillary pressure ↑]:::urgent D --> G E --> G F --> G G --> H[Pulmonary hemorrhage]:::urgent ``` **Clinical Pearl:** Maternal gestational diabetes (as in this case) is associated with delayed fetal lung maturation AND immature capillary endothelium, making these infants particularly vulnerable to pulmonary hemorrhage after surfactant. ### Management 1. **Immediate stabilization:** Maintain airway, increase ventilatory support (higher PEEP, increase FiO₂), correct hypotension with fluid bolus and inotropes (dopamine, dobutamine). 2. **Treat underlying PDA:** If present, consider indomethacin or ibuprofen (or surgical ligation if medical management fails). 3. **Supportive care:** Correct coagulopathy, maintain adequate hemoglobin, optimize ventilation to prevent further alveolar injury. 4. **Prognosis:** Mortality is significant (20–40%) if severe; survivors may have chronic lung disease. **High-Yield:** Pulmonary hemorrhage is NOT an anaphylactic reaction to surfactant itself — it is a hemodynamic consequence of rapid improvement in lung mechanics in a vulnerable infant with immature pulmonary vasculature.